COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03391050
Recruitment Status : Terminated (Target patient population - difficult to find patientes)
First Posted : January 5, 2018
Last Update Posted : July 31, 2019
Jules Bordet Institute
Information provided by (Responsible Party):
Aprea Therapeutics